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ABSTRACT
Active surveillance (AS) is currently a widely accepted treatment option for 
men with clinically localized prostate cancer (PCa). Several reports have highlighted 
the association of low serum testosterone levels with high-grade, high-stage PCa. 
However, the impact of serum testosterone as a predictor of progression in men with 
low-risk PCa has been little assessed.
In this study, we evaluated the association of circulating testosterone 
concentrations with a staging/grading reclassification in a cohort of low-risk PCa 
patients meeting the inclusion criteria for the AS protocol but opting for radical 
prostatectomy.
Radical prostatectomy (RP) was performed in 338 patients, eligible for AS 
according to the following criteria: clinical stage T2a or less, PSA<10ng/ml, two 
or fewer cancer cores, Gleason score (GS)≤6 and PSA density<0.2 ng/mL/cc. 
Reclassification was defined as upstaging (stage>pT2) and upgrading (GS≥7; primary 
Gleason pattern 4) disease. Unfavorable disease was defined as the occurrence of 
pathological stage>pT2 and predominant Gleason score 4. Total testosterone was 
measured before surgery.
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INTRODUCTION
Active surveillance (AS) has recently emerged 
as an alternative treatment for patients with low-
risk prostate cancer (PCa)-related mortality, whereby 
curative intervention can be delayed until the time that 
disease is re-classified or there is evidence of disease 
progression [1]. At present, urologists still suffer from a 
limited preoperative ability to reliably predict the tumor 
aggressiveness. Clinical stage, tumor grade (biopsy 
Gleason score) and prostate-specific antigen (PSA) are 
the established preoperative prognostic markers. However, 
despite these variables it is still difficult to determine 
which patients are candidates for AS. Literature data 
indicate a progression rate of about 30% in men on AS 
and a PCa-specific survival of < 97% at 5 years [2]. Thus, 
there is an urgent need of additional markers allowing us 
to discriminate between indolent or aggressive diseases.
Accumulating data indicate an important association 
between low testosterone concentrations and worrisome 
aspects of PCa. Multiple studies have reported the 
association of lower serum testosterone concentrations 
with high-grade PCa and a higher stage at presentation 
[3-6]. Furthermore, there is growing evidence supporting 
the theory that a drop in serum testosterone levels may 
modulate PCa risk and aggressiveness, since different 
metabolic disorders, such as obesity and metabolic 
syndrome (MetS), which are associated with low serum 
testosterone levels, have also been associated with an 
unfavorable PCa outcome [7, 8].
On this basis, total testosterone should be measured 
in patients with a localized PCa, in particularly when AS 
or nerve-sparing surgery is considered. In this study we 
explored the impact of serum testosterone on upgrading, 
upstaging, unfavorable disease, positive surgical margins 
and predominant Gleason score 4 in a cohort of patients 
with very low-risk PCa who met the inclusion criteria 
for Prostate Cancer Research International: Active 
Surveillance (PRIAS) protocol, but elected to undergo 
radical prostatectomy (RP). 
RESULTS
A total of 338 patients with PCa were enrolled in 
this study. Demographic and clinical characteristics of the 
overall study population are summarized in Ttable 1.
Total testosterone levels showed a significant 
association with all the main outcomes of interest (table 
2). In particular, when treated as a continuous variable, 
lower total testosterone levels (median [IQR]) were 
associated with reclassification in terms of upstaging 
(299.5 [250 ; 390] vs. 488.5 [401 ; 600]; p < 0.001), 
upgrading (400.5 [292.25 ; 534] vs. 497.5 [401 ; 600]; 
p < 0.001), unfavorable disease (290 [250 ; 300] vs. 456 
[390 ; 567]; p < 0.001) and predominant Gleason score 4 
(300 [254 ; 502] vs. 477 [398 ; 597]; p < 0.001) . These 
associations were confirmed when subjects were analysed 
according to the presence or absence of a hypogonadism 
condition (total testosterone < 300 ng/dL). In addition, 
we found a significantly higher rate of hypogonadism in 
PCa patients with positive surgical margins (27.8% vs. 
14.2%; p = 0.035). Of note, cancer involvement in positive 
cores (CIPC) was also significantly associated with all 
the outcomes (Table 2a and 2b). Receiver Operating 
Characteristic (ROC) curve analysis supported the 
prognostic role of total testosterone in the reclassification 
of men on AS (Figures 1-4). The corresponding area 
under the curve (AUC) ranged from 0.66 (95% C.I. 0.60 
to 0.72) for upgrading, to 0.81 (95% C.I. 0.75 to 0.88) 
Low serum testosterone levels (<300 ng/dL) were significantly associated with 
upgrading, upstaging, unfavorable disease and positive surgical margins. The addition 
of testosterone to a base model, including age, PSA, PSA density, clinical stage and 
positive cancer involvement in cores, showed a significant independent influence of 
this variable on upstaging, upgrading and unfavorable disease.
In conclusion, our results support the idea that total testosterone should be a 
selection criterion for inclusion of low-risk PCa patients in AS programs and suggest 
that testosterone level less than 300 ng/dL should be considered a discouraging factor 
when a close AS program is considered as treatment option
Figure 1: ROC Curve analysis for testosterone as a 
predictor of upstaging
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for upstaging. Sensitivities and specificities of total 
testosterone for each of the outcomes and according to 
both the “best combination” cut-off point and the cut-off 
point denoting a condition of hypogonadism are reported 
in table 3a and 3b. To assess the role of total testosterone 
as an independent predictor of reclassification, a set of 
multivariable logistic regression models including age, 
PSA, PSA density, digital rectal examination (DRE) status 
and cancer involvement in positive cores (CIPC) was 
constructed (Table 4). Total testosterone included in these 
base models was a significant independent predictor, both 
as a continuous and dichotomous variable, of upstaging, 
upgrading and unfavorable disease. However, a significant 
gain in predictive accuracy was only detected for the 
outcome of upstaging (15.2% when considering total 
testosterone as a continuous variable and 12.4% when 
treating total testosterone as a dichotomous variable) and 
predominant Gleason score 4 (9.4% or 8.3%, respectively). 
No advantages over the base model were observed for the 
outcome of upgrading, unfavourable disease and for the 
prediction of positive surgical margins.
Table 1: Clinical and Pathological Characteristics. 
Variable n=338Median [25th – 75th percentile]
Age, years 63.5 [59 ; 67]
PSA (ng/mL) 5.6 [4.29 ; 7.25]
PSA density 0.12 [0.09 ; 0.15]
Prostate Volume 49 [40.75 ; 55]
Familiarity, Yes 21 (6.2%)
PNI, Yes 20 (5.9%)
Nr of Positive Cores, 2 160 (47.3%)
Max % of core involved by tumor 20 [10 ; 30]
Positive DRE 36 (10.7%)
Testosterone (ng/dL) 451.5 [380 ; 566]
Testosterone <300ng/dL 53 (15.7%)
PNI, perineural invasion.
Table 2a: Clinical and pathological variables associated with tumor upstaging and upgrading. CIPC: cancer involvement 
in positive cores.
Upstaging Upgrading
No (n=272) Yes (n=66) p-value No (n=192) Yes (n=146) p-value
Age (years) 63.5 [59 ; 67] 63.5 [58.75 ; 66] 0.918 63 [58 ; 67] 64 [59.75 ; 67] 0.176
PSA (ng/mL) 5.68 [4.35 ; 7.3] 5.6 [4.12 ; 6.68] 0.584 5.55 [4.2 ; 7.3] 5.6 [4.43 ; 7.09] 0.834
PSA density 0.12 [0.09 ; 0.15] 0.12 [0.09 ; 0.15] 0.716 0.12 [0.09 ; 0.15] 0.12 [0.09 ; 0.15] 0.468
Prostate Volume 48 [40 ; 55] 49.5 [41 ; 54.25] 0.728 49 [41 ; 55] 48.5 [40 ; 55] 0.681
Familiarity, Yes 16 (5.9) 5 (7.6) 0.576 12 (6.3) 9 (6.2) 0.974
PNI. Yes 13 (4.8) 7 (10.6) 0.083 7 (3.6) 13 (8.9) 0.042
Nr of Positive Cores, 2 122 (44.9) 38 (57.6) 0.063 86 (44.8) 74 (50.7) 0.282
CIPC (%) 20 [10 ; 30] 40 [30 ; 50] <0.001 20 [10 ; 30] 30 [20 ; 45] <0.001
Positive DRE 26 (9.6) 10 (15.2) 0.186 18 (9.4) 18 (12.3) 0.477
Testosterone (ng/dL) 488.5 [401 ; 600] 299.5 [250 ; 390] <0.001 497.5 [401 ; 600] 400.5 [292.25 ; 534] <0.001
Testosterone <300 ng/dL 20 (7.4) 33 (50) <0.001 13 (6.8) 40 (27.4) <0.001
DRE: Digital rectal examination; PNI: perineural invasion; PSA: prostate-specific antigen
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DISCUSSION
The principal aim of an AS program is to reduce 
over-treatment in patients with clinically confined, 
very-low-risk PCa, without compromising curative 
treatment [9]. The identification of these low risk PCa is 
still a critical issue today, and many markers have been 
identified for selecting candidates for non-aggressive 
therapies [10-16]. Although the selection criteria for 
AS include stringent clinicopathological parameters, it 
is well established that about a third of men on AS will 
undergo progression requiring active treatment [1, 17]. 
Table 2b: Clinical and pathological variables associated with unfavorable disease, positive surgical margins and 
predominant Gleason score 4. 
Unfavorable Disease Positive margins Predominant Gleason 4
No (n=316) Yes (n=22) pvalue No (n=302) Yes (n=36) p-value No (n=276) Yes (n=62) pvalue
Age (years) 63.5 [59 ; 67] 63.5 [59.5 ; 66] 0,904 64 [59 ; 67] 61.5 [55.5 ; 65] 0.136 63 [58 ; 67] 64.5 [60 ; 68] 0,168
PSA (ng/mL) 5.6 [4.4 ; 7.3] 5.5 [4 ; 6.3] 0,244 5.64 [4.29 ; 7.25] 5.03 [4.14 ; 7.27] 0.451 5.6 [4.4 ; 7.3] 5.6 [4.1 ; 7] 0,43
PSA density 0.12 [0.09 ; 0.15] 0.11 [0.06 ; 0.14] 0,068 0.12 [0.09 ; 0.15] 0.12 [0.09 ; 0.15] 0.925 0.12 [0.09 ; 0.15] 0.11 [0.07 ; 0.15] 0,073
Prostate Volume 48 [40 ; 55] 52 [41 ; 61.3] 0,085 49 [41 ; 55] 45 [38.5 ; 53.75] 0.102 47.5 [40 ; 55] 51.5 [41 ; 60] 0,011
Familiarity, Yes 20 (6.3) 1 (4.5) 1,000 19 (6.3) 2 (5.6) 1.000 17 (6.2) 4 (6.5) 1,000
PNI, Yes 17 (5.4) 3 (13.6) 0,132 17 (5.6) 3 (8.3) 0.458 9 (3.3) 11 (17.7) <0.001
Nr of Positive Cores. 
2 146 (46.2) 14 (63.6) 0,123 146 (48.3) 14 (38.9) 0.283 129 (46.7) 31 (50) 0,642
CIPC (%) 25 [10 ; 35] 40 [30 ; 60] <0.001 25 [10 ; 35] 30 [20 ; 40] 0.027 20 [10 ; 30] 40 [30 ; 50] <0.001
Positive DRE 32 (10.1) 4 (18.2) 0,273 32 (10.6) 4 (11.1) 1.000 28 (10.1) 8 (12.9) 0,525
Testosterone (ng/dL) 456 [390 ; 567] 290 [250 ; 300] <0.001 456 [389 ; 566.25] 400.5 [290 ; 540.5] 0.0643 477 [398.3 ; 597.3] 300 [254.5 ; 502] <0.001
Testosterone <300 
ng/dL 39 (12.3) 14 (63.6) <0.001 43 (14.2) 10 (27.8) 0.035 25 (9.1) 28 (45.2) <0.001
CIPC: cancer involvement in positive cores; DRE: Digital rectal examination; PNI: perineural invasion; PSA: prostate-specific 
antigen
Table 3a: Sensitivities and specificities of total testosterone for each of the outcomes
Testoterone (ng/dL) Sensitivity (95% C.I.) Specificity (95% C.I.)
Upstaging 344 0.70 (0.59 to 0.8) 0.90 (0.86 to 0.93)
Upgrading 431 0.60 (0.52 to 0.67) 0.70 (0.63 to 0.77)
Unfavorable disease 302 0.85 (0.81 to 0.89) 0.82 (0.64 to 0.95)
Predominant Gleason 4 315 0.53 (0.4 to 0.66) 0.87 (0.83 to 0.91)
Table 3b:  Sensitivities and specificities of testosterone < 300 ng/dL (hypogonadism) for each of the outcomes
Hypogonadism condition
Testosterone (ng/dL) Sensitivity (95% C.I.) Specificity (95% C.I.)
Upstaging 300 0.65 (0.53 to 0.76) 0.92 (0.89 to 0.95)
Upgrading 300 0.34 (0.27 to 0.42) 0.92 (0.89 to 0.96)
Unfavorable disease 300 0.85 [0.81 to 0.89] 0.82 [0.64 to 0.95]
Predominant Gleason 4 300 0.52 (0.39 to 0.65) 0.88 (0.84 to 0.92)
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Table 4: Multivariable logistic regression models including age, PSA, PSA density, DRE status and CIPC for tumor 
upstaging, upgrading, unfavorable disease,  positive surgical margins and predominant Gleason 4.
Upstaging
Continous TT TT≥300ng/dLTT<300ng/dL
O.R. [95% C.I.] p-value O.R. [95% C.I.] p-value
Age 0.94 [0.89 to 1] 0,036 0.95 [0.9 to 1] 0,063
PSA (ng/mL) 1.22 [0.93 to 1.6] 0,149 1.15 [0.89 to 1.5] 0,29
PSA Density, 0.1 increase 0.47 [0.14 to 1.62] 0,231 0.45 [0.13 to 1.51] 0,193
Positive DRE 1.31 [0.48 to 3.55] 0,600 1.14 [0.42 to 3.12] 0,798
CIPC 1.05 [1.03 to 1.07] <0.001 1.05 [1.03 to 1.07] <0.001
Testosterone, 10 ng/dl increase 0.92 [0.89 to 0.94] <0.001
Testosterone, <300 ng/dL   11.62 [5.43 to 24.85] <0.001
AUC, [95% C.I.] 0.84 [0.79 to 0.9] 0.81 [0.75 to 0.88]
Gain in predictive accuracy; % (p-value) 15.2 (<0.001) 12.4 (0.002)
Upgrading
Continous TT TT≥300ng/dLTT<300ng/dL
O.R. [95% C.I.] p-value O.R. [95% C.I.] p-value
Age 1.01 [0.96 to 1.05] 0,827 1.01 [0.96 to 1.05] 0,791
PSA (ng/mL) 1.02 [0.84 to 1.24] 0,868 1.02 [0.83 to 1.24] 0,87
PSA Density, 0.1 increase 1.07 [0.43 to 2.63] 0,890 0.97 [0.39 to 2.39] 0,945
Positive DRE 1.18 [0.54 to 2.6] 0,674 1.14 [0.51 to 2.53] 0,754
CIPC 1.05 [1.03 to 1.07] <0.001 1.05 [1.03 to 1.07] <0.001
Testosterone, 10 ng/dl increase 0.97 [0.96 to 0.99] 0,001
Testosterone, <300 ng/dL   3.6 [1.74 to 7.46] 0,001
AUC, [95% C.I.] 0.73 [0.68 to 0.79] 0.73 [0.68 to 0.79]
Gain in predictive accuracy; % (p-value) 0.1 (0.935) 0.1 (0.922)
Unfavorable Disease
Continous TT TT≥300ng/dLTT<300ng/dL
O.R. [95% C.I.] p-value O.R. [95% C.I.] p-value
Age 0.95 [0.88 to 1.03] 0,217 0.95 [0.87 to 1.03] 0,197
PSA (ng/mL) 1.29 [0.86 to 1.93] 0,222 1.26 [0.82 to 1.92] 0,287
PSA Density, 0.1 increase 0.14 [0.02 to 0.87] 0,035 0.12 [0.02 to 0.88] 0,037
Positive DRE 1.23 [0.34 to 4.47] 0,754 1.03 [0.27 to 3.94] 0,968
CIPC 1.05 [1.02 to 1.08] 0,001 1.05 [1.02 to 1.08] 0,002
Testosterone, 10 ng/dl increase 0.93 [0.89 to 0.97] 0,001
Testosterone, <300 ng/dL 10.26 [3.54 to 29.76] <0.001
AUC, [95% C.I.] 0.84 [0.77 to 0.92] 0.84 [0.73 to 0.95]
Gain in predictive accuracy; % (p-value) 6.3 (0.119) 5.9 (0.101)
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Positive margins
Continous TT TT≥300ng/dLTT<300ng/dL
O.R. [95% C.I.] p-value O.R. [95% C.I.] p-value
Age 0.95 [0.89 to 1.01] 0,075 0.95 [0.89 to 1.01] 0,072
PSA (ng/mL) 0.85 [0.63 to 1.15] 0,295 0.85 [0.63 to 1.14] 0,269
PSA Density, 0.1 increase 1.85 [0.5 to 6.83] 0,358 1.79 [0.49 to 6.53] 0,379
Positive DRE 0.85 [0.26 to 2.7] 0,776 0.84 [0.27 to 2.69] 0,774
CIPC 1.02 [0.99 to 1.04] 0,191 1.02 [0.99 to 1.04] 0,205
Testosterone, 10 ng/dl increase 0.98 [0.96 to 1] 0,097
Testosterone, <300 ng/dL   2.25 [0.94 to 5.43] 0,07
AUC, [95% C.I.] 0.66 [0.56 to 0.76] 0.66 [0.57 to 0.75]
Gain in predictive accuracy; % (p-value) 0.74 (0.934) 1.11 (0.904)
Predominant Gleason 4
Continous TT TT≥300ng/dLTT<300ng/dL
O.R. [95% C.I.] p-value O.R. [95% C.I.] p-value
Age 1 [0.95 to 1.06] 0,996 1 [0.94 to 1.06] 0,916
PSA (ng/mL) 1.3 [0.99 to 1.71] 0,054 1.3 [0.99 to 1.71] 0,058
PSA Density, 0.1 increase 0.16 [0.05 to 0.56] 0,004 0.13 [0.04 to 0.49] 0,002
Positive DRE 0.86 [0.32 to 2.28] 0,755 0.72 [0.26 to 2.05] 0,543
CIPC 1.06 [1.04 to 1.08] <0.001 1.06 [1.04 to 1.08] <0.001
Testosterone, 10 ng/dl increase 0.96 [0.93 to 0.98] <0.001
Testosterone, <300 ng/dL 6.66 [3.14 to 14.15] <0.001
AUC, [95% C.I.] 0.81 [0.75 to 0.87] 0.82 [0.75 to 0.89]
Gain in predictive accuracy; % (p-value) 8.3 (0.046) 9.4 (0.041)
For sake of readability of the results, when treating Testosterone as continuous predictor, the Odds Ratio have been computed 
for a 10ng/dl increase in TT levels. Testosterone has been analyzed both as continuous and as dichotomous predictor using 
300ng/dl as cut-off. CIPC: cancer involvement in positive cores; DRE: Digital rectal examination; PNI: perineural invasion; 
PSA: prostate-specific antigen
Figure 2: ROC Curve analysis for testosterone as a 
predictor of upgrading
Figure 3: ROC Curve analysis for testosterone as a 
predictor of unfavorable disease
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Therefore, there is a strong interest in finding risk factors 
for reclassification and progression, particularly in men 
with a long life expectancy [18]. Conflicting results have 
been reported on the risk/benefit ratio of AS as upfront 
treatment strategy allowing radical treatment to be delayed 
or avoided [19-22]. Therefore, an important focus for AS 
protocols is to improve the selection of patients at the time 
of inclusion in order to minimize the reclassification of 
risk during follow-up. In this context, several tools have 
been proposed to overcome these limitations of current AS 
protocols. Multiparametric magnetic resonance imaging 
(MRI) [23], urinary (prostate cancer antigen 3) and serum 
markers [24], histopathological [25-27] and genetic factors 
[28-30] have been analyzed.
Little is yet known about the clinical utility of 
serum testosterone levels as a predictor of disease 
reclassification in men on AS. Recently, in a relatively 
small population San Francisco et al [31] showed that free, 
but not total testosterone levels nor the free testosterone/
total testosterone ratio or the testosterone/PSA ratio, 
were significantly lower in men with PCa and disease 
reclassification during AS. A number of previous reports 
identified a significant relationship between a high Gleason 
score and low testosterone levels [32-35]. Furthermore, 
growing evidence supports the idea that a decreased serum 
testosterone concentration, related to different metabolic 
disorders including obesity and metabolic syndrome, may 
modulate PCa aggressiveness [36].
We assessed the use of serum total testosterone 
as a predictor of disease reclassification in a cohort of 
men eligible for AS according to PRIAS criteria. Our 
results showed that men who underwent reclassification 
had significantly lower serum total testosterone levels 
compared to those who were not reclassified (p < 0.001). 
By ROC curve analysis, we identified a testosterone 
threshold of 344 ng/dL, 431 ng/dL, 302 ng/dL and 315 
for upstaging, upgrading, unfavorable disease and 
predominant Gleason score 4 respectively. Men with 
testosterone levels lower than these values had a higher 
risk of disease reclassification. When the threshold value 
for hypogonadism ( < 300ng/dL) was used as cut-off [6, 
37], we found significantly more patients with upstaging, 
upgrading, unfavorable disease, positive surgical margins 
and predominant Gleason score 4 compared to eugonadal 
patients. Multivariate analysis indicated that serum total 
testosterone, used either as a continuous or a dichotomous 
variable, was an independent predictor of upgrading, 
upstaging, unfavorable disease and predominant Gleason 
score 4.
 Pichon et al [33] had shown in a larger study 
population that a low serum testosterone level was 
an independent predictor of a predominant Gleason 
pattern 4 at radical prostatectomy and of upgrading from 
low- to high-grade PCa between needle biopsies and 
prostatectomy specimens. Accordingly, the San Francisco 
et al study [31] showed that men on AS with low serum 
free testosterone levels had more than four times the risk 
of disease reclassification, suggesting the need for further 
studies to assess testosterone as a tool to better select 
patients for AS. 
Collectively, our results suggest the importance 
of taking into account hypogonadism and metabolic 
disorders such as obesity and metabolic syndrome, as 
selection criteria for patients inclusion in AS programs. 
Consistently, the majority of large observational series 
have shown that obesity is a risk factor for adverse 
pathologic features, a more advanced stage, higher risk 
for biochemical recurrence after RP, and risk of death from 
PCa [7, 38, 39]. 
Our findings support the use of total testosterone 
as a predictor of disease reclassification for men with 
PCa undergoing AS. Moreover, our models including 
testosterone showed a significant gain in predictive 
accuracy of upstaging and unfavorable disease.
These data are consistent with the idea that patients 
with low serum testosterone levels are more likely to have 
aggressive PCa. AS protocols in these patients should 
ensure close monitoring of PSA levels and imaging 
examinations, in order to identify tumor progression as 
early as possible.
The strength of this study is the large population 
(338 patients on AS), allowing a robust statistical 
analysis. Furthermore, as recommended by the 
Endocrine Society guidelines, all blood samples for 
testosterone were analyzed suing the same platform, 
and were collected between 07:00 to 10:00 hours, in 
order to avoid circadian variations and inter-assay 
variability. Total testosterone was measured with one 
of the best electrochemiluminescent immunoassays 
and the histological analysis of prostate biopsies and 
prostatectomy specimens was done by three senior 
Figure 4: ROC Curve analysis for testosterone as a 
predictor of predominant Gleason score 4
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uropathologists avoiding variability in Gleason scores 
interpretation. Moreover, exclusion criteria were strictly 
defined to rule out patients that had received neoadjuvant 
hormonal therapy or affected by other comorbidities that 
can affect the testosterone levels.
However, some limitations have to be taken into 
account. Firstly, our study was carried out retrospectively, 
and several useful measures that affect testosterone values, 
such as SHBG, luteinizing hormone and oestradiol, 
were not determined. In addition, like previous reports 
on the correlation between hypogonadism and a poor 
outcome in PCa, we did not use mass-spectrometry-based 
measurements, recently advocated as the gold standard 
for sex steroid quantifications [40]. Finally, we lacked 
data about free and bioavailable testosterone, which were 
demonstrated to be important in a previous report [31]. 
The focus was primarily on the pathological findings, 
but we did not assess biochemical recurrence or prostate 
cancer-specific mortality, which might be a more important 
issue than the adverse pathological characteristics to better 
define progression. In fact, it is well accepted that disease 
reclassification may be the result of sampling error [41].
In conclusion, men with hypogonadism eligible for 
AS are at higher risk of disease upgrading and upstaging 
compared to men with normal serum testosterone 
levels. These results highlight the utility of evaluating 
testosterone levels in patients with localized PCa, eligible 
for AS. Further prospective studies on large populations, 
with mass-spectrometry-based testosterone measurements 
and SHBG, luteinizing hormone, oestradiol, free and 
bioavailable testosterone data are needed to confirm our 
findings and support the use of circulating sex hormones 
as prognostic biomarkers in patients eligible for AS.
MATERIALS AND METHODS
Patients
Between January 2009 and December 2015, 338 
consecutive men were referred for localized PCa, and 
underwent, within 3 months of diagnosis, laparoscopic 
or robot-assisted laparoscopic RP at three tertiary care 
institutions (Departments of Urology of the National 
Cancer Institute “Fondazione Pascale”-Naples, of the 
University of Catanzaro and of the University of Bari).
Patients fulfilled the inclusion criteria for the PRIAS 
protocol [42] defined as: clinical stage T2a or less, PSA < 
10 ng/ml, 2 or less cancer involvement cores after a biopsy 
scheme of at least 12 cores, Gleason score (GS)≤6 and 
PSA density < 0.2 ng/mL/cc .
Patho logical findings in prostate biopsies were 
compared with pathological specimens after RP. 
Reclassification was defined as disease upstaging 
(pathological stage>pT2) and upgrading (GS ≥ 7; primary 
Gleason pattern 4). Unfavorable disease was defined as the 
occurrence of pathological stage>pT2 and predominant 
Gleason score 4.
RP specimens were processed and evaluated 
according to the Stanford protocol [43] by three 
experienced genitourinary pathologists, blinded to the 
index-tests results of each Institution.
For all patients, at least 12 core biopsies were 
analyzed according to the 2005 International Society 
of Urological Pathology recommendations [44]. None 
of the study patients received neoadjuvant hormonal 
therapy (antiandrogens or luteinizing hormone-releasing 
hormone analogues or antagonists) or other hormonal 
preparations (i.e., 5-α reductase inhibitors) that could alter 
their PSA values. We also excluded patients with acute 
bacterial prostatitis or previous prostate surgery in the 3 
months before biopsy. In addition, subjects with chronic 
renal disease, marked alterations in blood protein levels, 
hemophilia, incurable endocrine diseases or those who 
had previously undergone multiple transfusions, were 
excluded from the study because these conditions could 
alter the concentration of total PSA and testosterone.
Data collected included age, preoperative PSA 
level, PSA density, clinical stage and preoperative serum 
testosterone levels.
The threshold for hypogonadism was set at a 
total testosterone level of 300 ng/dL, in agreement with 
the American Association of Clinical Endocrinologist 
guidelines [37]. Accordingly, patients were further divided 
into two groups: 1) low total testosterone group ( < 300 
ng/dL) and 2) normal testosterone group (≥300 ng/dL). 
Clinical stage was assessed by digital rectal examination 
and magnetic resonance imaging by the attending surgeon 
according to TNM staging (2009). Disease upstaging was 
regarded as pathological stage ≥T3a after RP with clinical 
stage ≤T2c. Prostate cancer upgrading was defined as GS 
≥7 in RP specimens with GS ≤6 in needle biopsies. 
This study received approval from the local hospital 
ethics committee (i.e. institutional review board approval). 
Written informed consent was obtained from all patients.
Hormonal assay
All patients underwent systematic blood sampling 
between 7 AM and 10 AM on the day before surgery to 
assess serum total testosterone concentrations.
Electrochemiluminescence immuno-assays, using 
high-affinity monoclonal antibodies, were performed 
at the laboratories of the three Institutions, blinded to 
the pathological results, using Testosterone ElecsysII 
(Modular Analytics E170 -Roche, Basel, Switzerland).
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Statistical analysis
Numerical variables were recorded and analysed 
as median [25th - 75th percentile] while categorical 
variables were expressed as frequencies and percentages. 
Comparisons between groups were based on the Mann-
Whitney or Chi square tests. The predictive accuracy 
of testosterone was evaluated using Receiver Operating 
Characteristic (ROC) analysis and quantified in terms of 
Area Under the Curve (AUC) and corresponding 95% 
confidence interval (95% C.I.). The independent role of 
testosterone in predicting pathological outcomes at radical 
prostatectomy was assessed using multivariable logistic 
regression models; a bootstrap approach, based on 1999 
bootstrap replications, was used to compare the percentage 
change in predictive accuracy (in terms of AUC) between 
nested logistic models.
Statistical analyses and modelling were performed 
with R statistical computing software (R Foundation for 
Statistical Computing, Vienna, Austria). P-values < 0.05 
were considered statistically significant.
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